A second article, also published on 19th November in Nature Communications, further demonstrates the potential beneficial effect of Tamoxifen for x-linked myotubular myopathy.
You can read the full published article in Nature Communications here: Tamoxifen prolongs survival and alleviates symptoms in mice with fatal x-linked myotubular myopathy 2018, Gayi et al
How do these articles about the impact of Tamoxifen in Nature Communications relate?
The work described in the two papers published, was performed by different research teams. They had the same overall result – showing the potential of Tamoxifen for x-linked myotubular myopathy. The publications were submitted back-to-back to the same journal, rather than competing with each other in an effort to strengthen the research ongoing in the centronuclear research community and will hopefully promote further collaborations going forwards. Two different papers from two different team in fact further strengthens the potential and impact of the work.
Also both publications provide a larger perspective of the effect of Tamoxifen in x-linked myotubular myopathy, as both investigators, Dr J Dowling et al and Dr E Gayi et al, focussed on different aspects of the impact of the drug on the symptoms of the condition.
You can read Dr J Dowling’s article here: Tamoxifen therapy in a murine model of myotubular myopathy 2018 J Dowling et al